Sarepta Therapeutics (SRPT) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Sarepta Therapeutics (SRPT) over the last 14 years, with Q4 2024 value amounting to $37.7 million.
- Sarepta Therapeutics' Accumulated Depreciation & Amortization fell 1503.03% to $37.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $37.7 million, marking a year-over-year decrease of 1503.03%. This contributed to the annual value of $37.7 million for FY2024, which is 1503.03% down from last year.
- Latest data reveals that Sarepta Therapeutics reported Accumulated Depreciation & Amortization of $37.7 million as of Q4 2024, which was down 1503.03% from $44.4 million recorded in Q4 2023.
- In the past 5 years, Sarepta Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $112.6 million in Q4 2021 and a low of $37.7 million during Q4 2024
- For the 5-year period, Sarepta Therapeutics' Accumulated Depreciation & Amortization averaged around $62.5 million, with its median value being $44.4 million (2023).
- In the last 5 years, Sarepta Therapeutics' Accumulated Depreciation & Amortization surged by 4908.72% in 2020 and then tumbled by 6283.12% in 2022.
- Sarepta Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $76.0 million in 2020, then surged by 48.15% to $112.6 million in 2021, then tumbled by 62.83% to $41.9 million in 2022, then grew by 6.05% to $44.4 million in 2023, then dropped by 15.03% to $37.7 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $37.7 million for Q4 2024, versus $44.4 million for Q4 2023 and $41.9 million for Q4 2022.